Keywords: Pfizer, Tofacitinib, Rheumatoid arthritis, Phase III trial, Patient deaths

Patient death linked to Pfizer’s RA drug candidate tofacitinib

Article | 26 April 2011

Print This

Global drugs behemoth Pfizer (NYSE: PFE) saw its share drop 3,6% to $19.67 after the company commented on an abstract concerning the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in